NEWS: NICE has recommended capivasertib for advanced #BreastCancer.

The decision makes the targeted drug available, in combination with fulvestrant, for some NHS patients with the most common type of breast cancer.

Read more about the history of the drug⬇️
https://www.icr.ac.uk/about-us/icr-news/detail/icr-welcomes-nice-recommendation-of-capivasertib-for-advanced-breast-cancer